According to results from a randomized, placebo- controlled study presented at the meeting, the combination of glucosamine, sodium chondroitin sulfate and manganese ascorbate was effective in the treatment of mild to moderate osteoarthritis of the knee, as reflected in an improvement in the Lesquene index of severity of osteoarthritis of the knee. Statistical significance was reached at both four and six months. In the US, there are 365,000 CABG procedures and 80,000 valve surgeries annually. Many patients who undergo these procedures require additional follow-up surgeries. Reoperative cardiac surgery is associated with increased risks, in part because of the presence of adhesions that form following the initial surgery.
Adhesions make operations more difficult to perform and thus more dangerous to the patient.
Both the complexity and duration of followup surgeries are increased when it is necessary to separate adhesions. The approval expands the indication for Seprafilm in Europe, where the product has been used for three years to reduce the incidence of adhesions following abdominal and pelvic surgeries. Seprafilm II is a second-generation product designed to have improved handling properties. Seprafilm in the US for reducing the incidence of adhesions following abdominal and pelvic surgeries. Seprafilm II is used in both open and laparoscopic surgical procedures to reduce the incidence of post- surgical abdominal and pelvic adhesions.